NCT03887741 is a Phase 1 clinical trial of Plasmapheresis in Mild Cognitive Impairment, sponsored by Mayo Clinic.

Who is sponsoring NCT03887741?

NCT03887741 is sponsored by Mayo Clinic.

What drugs are being tested in NCT03887741?

Interventions in NCT03887741: Plasmapheresis, Plasma infusion.

What condition does NCT03887741 study?

NCT03887741 studies Mild Cognitive Impairment.

Is NCT03887741 still recruiting?

NCT03887741 is currently completed. Last updated 31 December 2024.

Last reviewed 2024-12-31 · How we verify

NCT03887741

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Plasmapheresis Versus Plasma Infusion from Young APOE3 Homozygotes Into MCI APOE4 Homozygotes to Slow Disease Progression

Completed Phase 1 Last updated 31 December 2024

What this trial tests

Phase 1 trial testing Plasmapheresis in Mild Cognitive Impairment in 3 participants. Completed in 16 February 2024.

Timeline

15 September 2021

Primary endpoint
16 February 2024

16 February 2024

Quick facts

Lead sponsor	Mayo Clinic
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	3
Start date	15 September 2021
Primary completion	16 February 2024
Estimated completion	16 February 2024
Sites	1 location across United States

Drugs / interventions tested

Plasmapheresis — full drug profile →
Plasma infusion — full drug profile →

Conditions studied

Mild Cognitive Impairment — all drugs for Mild Cognitive Impairment →

Sponsor

Mayo Clinic

Who can join

Adults 50 to 75, any sex, with Mild Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Determine safety of plasma infusion or exchange in APOE 44 patients.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies.
Raulin AC, Doss SV, Trottier ZA, Ikezu TC, et al · · 2022 · cited 449× · PMID 36348357 · DOI 10.1186/s13024-022-00574-4
APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer's disease pathology and brain diseases.
Fernández-Calle R, Konings SC, Frontiñán-Rubio J, García-Revilla J, et al · · 2022 · cited 198× · PMID 36153580 · DOI 10.1186/s13024-022-00566-4

Verify or expand the search:

Other trials of Plasmapheresis

Trials testing the same drug.

NCT07087860 — Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers · Phase 2 · recruiting
NCT06597656 — A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therape · Phase 1 · terminated
NCT05562960 — Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP · NA · recruiting
NCT05815615 — Plasmapheresis: a Multi-modal Approach · NA · completed
NCT05179200 — The Effect of Plasma Donation Frequency on Donor Health · NA · completed

Other recruiting trials for Mild Cognitive Impairment

Currently open trials in the same condition.

NCT05791994 — EVASION: Effect of VisuAl Stimulation on attentION · NA · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07220694 — Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairmen · NA · recruiting
NCT06983769 — CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial · NA · recruiting
NCT07318038 — The Use of Rhythmic Light Therapy in Mild Cognitive Impairment · NA · recruiting

Other Mayo Clinic trials

Trials by the same sponsor.

NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance, · NA · not yet recruiting
NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE) · NA · recruiting
NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03887741 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
Last refreshed: 31 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03887741.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing